Critical Study on Topical CuradermBEC5 Therapy for Periocular Nonmelanoma Skin Cancers: A Review of Clinical Outcomes

Approximately 5 to 10 percent of all skin cancers occur in the periocular region. Basal cell carcinoma
is the most frequent malignant periocular tumor, followed by squamous cell carcinoma, sebaceous
gland carcinoma, and malignant melanoma. Nonmelanoma skin tumors at the periocular area often
cause disfigurement with destruction of soft conjunctival tissue. Many therapeutic methods have been
recommended to combat the morbidity and mortality associated with these lesions. Excisions with
frozen-section control or Mohs micrographic surgery are regarded as the gold-standard treatments for
periocular basal cell and squamous cell carcinomas. However, these treatment modalities have
various limitations and reconstruction surgery is often associated with these treatment options. The
chemotherapeutic agents solasodine rhamnosides in a cream formulation CuradermBEC5 are specific,
effective and safe treatments for nonmelanoma skin cancers with excellent cosmesis. The
antineoplastic mode of action is by apoptosis. In this review it is shown that CuradermBEC5 also treats
periocular basal cell carcinoma and squamous cell carcinoma with impressive cosmetic outcomes and
no reconstructive surgery is required.